361 related articles for article (PubMed ID: 18489519)
1. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.
Tan MC; Marra CA; Sadatsafavi M; Marra F; Morán-Mendoza O; Moadebi S; Elwood RK; FitzGerald JM
Value Health; 2008; 11(5):842-52. PubMed ID: 18489519
[TBL] [Abstract][Full Text] [Related]
2. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.
Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L
Value Health; 2013; 16(1):66-75. PubMed ID: 23337217
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.
Marra F; Marra CA; Sadatsafavi M; Morán-Mendoza O; Cook V; Elwood RK; Morshed M; Brunham RC; Fitzgerald JM
Int J Tuberc Lung Dis; 2008 Dec; 12(12):1414-24. PubMed ID: 19017451
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.
Diel R; Nienhaus A; Loddenkemper R
Chest; 2007 May; 131(5):1424-34. PubMed ID: 17494792
[TBL] [Abstract][Full Text] [Related]
5. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.
Mandalakas AM; Hesseling AC; Gie RP; Schaaf HS; Marais BJ; Sinanovic E
Thorax; 2013 Mar; 68(3):247-55. PubMed ID: 22717944
[TBL] [Abstract][Full Text] [Related]
6. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.
Pooran A; Booth H; Miller RF; Scott G; Badri M; Huggett JF; Rook G; Zumla A; Dheda K
BMC Pulm Med; 2010 Feb; 10():7. PubMed ID: 20170555
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.
Kowada A; Takasaki J; Kobayashi N
J Hosp Infect; 2015 Feb; 89(2):99-108. PubMed ID: 25559158
[TBL] [Abstract][Full Text] [Related]
8. Priorities for screening and treatment of latent tuberculosis infection in the United States.
Linas BP; Wong AY; Freedberg KA; Horsburgh CR
Am J Respir Crit Care Med; 2011 Sep; 184(5):590-601. PubMed ID: 21562129
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.
Oxlade O; Schwartzman K; Menzies D
Int J Tuberc Lung Dis; 2007 Jan; 11(1):16-26. PubMed ID: 17217125
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.
Shrestha RK; Mugisha B; Bunnell R; Mermin J; Hitimana-Lukanika C; Odeke R; Madra P; Adatu F; Blandford JM
Int J Tuberc Lung Dis; 2006 Jun; 10(6):656-62. PubMed ID: 16776453
[TBL] [Abstract][Full Text] [Related]
11. Risk for Tuberculosis Disease Among Contacts with Prior Positive Tuberculin Skin Test: A retrospective Cohort Study, New York City.
Gounder PP; Harris TG; Anger H; Trieu L; Meissner JS; Cadwell BL; Shashkina E; Ahuja SD
J Gen Intern Med; 2015 Jun; 30(6):742-8. PubMed ID: 25605533
[TBL] [Abstract][Full Text] [Related]
12. Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore.
Chee CB; Teleman MD; Boudville IC; Do SE; Wang YT
Int J Tuberc Lung Dis; 2004 Feb; 8(2):226-31. PubMed ID: 15139452
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country.
Brassard P; Steensma C; Cadieux L; Lands LC
Pediatrics; 2006 Feb; 117(2):e148-56. PubMed ID: 16452324
[TBL] [Abstract][Full Text] [Related]
14. Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts.
Morán-Mendoza O; Marion SA; Elwood K; Patrick DM; FitzGerald JM
Int J Tuberc Lung Dis; 2007 Sep; 11(9):1014-20. PubMed ID: 17705981
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis.
Diel R; Wrighton-Smith P; Zellweger JP
Eur Respir J; 2007 Aug; 30(2):321-32. PubMed ID: 17504793
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.
Deuffic-Burban S; Atsou K; Viget N; Melliez H; Bouvet E; Yazdanpanah Y
Int J Tuberc Lung Dis; 2010 Apr; 14(4):471-81. PubMed ID: 20202306
[TBL] [Abstract][Full Text] [Related]
18. Predictors of contact tracing completion and outcomes in tuberculosis: a 21-year retrospective cohort study.
Saunders MJ; Koh GC; Small AD; Dedicoat M
Int J Tuberc Lung Dis; 2014 Jun; 18(6):640-6. PubMed ID: 24903932
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.
de Perio MA; Tsevat J; Roselle GA; Kralovic SM; Eckman MH
Arch Intern Med; 2009 Jan; 169(2):179-87. PubMed ID: 19171815
[TBL] [Abstract][Full Text] [Related]
20. [Comparative performance of tuberculin skin test and QuantiFERON TB-gold in contact investigations for tuberculosis].
Komukai J; Matsumoto K; Tomihara A; Miyake Y; Tatsumi T; Arima K; Danno K; Hirota S; Yoshida H; Koda S; Terakawa K; Shimouchi A
Kekkaku; 2011 Nov; 86(11):847-56. PubMed ID: 22250463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
